175 related articles for article (PubMed ID: 19394272)
1. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics.
Dolly JO; Lawrence GW; Meng J; Wang J; Ovsepian SV
Curr Opin Pharmacol; 2009 Jun; 9(3):326-35. PubMed ID: 19394272
[TBL] [Abstract][Full Text] [Related]
2. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.
Meng J; Wang J; Lawrence G; Dolly JO
J Cell Sci; 2007 Aug; 120(Pt 16):2864-74. PubMed ID: 17666428
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
Dolly JO; Wang J; Zurawski TH; Meng J
FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
5. Activity-dependent changes in partial VAMP complexes during neurotransmitter release.
Hua SY; Charlton MP
Nat Neurosci; 1999 Dec; 2(12):1078-83. PubMed ID: 10570484
[TBL] [Abstract][Full Text] [Related]
6. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain.
Dolly JO; O'Connell MA
Curr Opin Pharmacol; 2012 Feb; 12(1):100-8. PubMed ID: 22188874
[TBL] [Abstract][Full Text] [Related]
7. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
8. A botulinum neurotoxin-like function of Potentilla chinensis extract that inhibits neuronal SNARE complex formation, membrane fusion, neuroexocytosis, and muscle contraction.
Jung CH; Choi JK; Yang Y; Koh HJ; Heo P; Yoon KJ; Kim S; Park WS; Shing HJ; Kweon DH
Pharm Biol; 2012 Sep; 50(9):1157-67. PubMed ID: 22881141
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the mechanisms of synaptotagmin and SNARE function in neurotransmitter release.
Rizo J; Chen X; Araç D
Trends Cell Biol; 2006 Jul; 16(7):339-50. PubMed ID: 16698267
[TBL] [Abstract][Full Text] [Related]
10. Identification of SNAREs that mediate zymogen granule exocytosis.
Pickett JA; Campos-Toimil M; Thomas P; Edwardson JM
Biochem Biophys Res Commun; 2007 Aug; 359(3):599-603. PubMed ID: 17544372
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SNARE-driven neuroexocytosis by plant extracts.
Jung CH; Yang YS; Kim JS; Shin YK; Hwang JS; Son ED; Lee HH; Chung KM; Oh JM; Lee JH; Kweon DH
Biotechnol Lett; 2009 Mar; 31(3):361-9. PubMed ID: 19023663
[TBL] [Abstract][Full Text] [Related]
13. Regulation of exocytotic protein expression and Ca2+-dependent peptide secretion in astrocytes.
Paco S; Margelí MA; Olkkonen VM; Imai A; Blasi J; Fischer-Colbrie R; Aguado F
J Neurochem; 2009 Jul; 110(1):143-56. PubMed ID: 19594665
[TBL] [Abstract][Full Text] [Related]
14. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins.
Dolly O
Headache; 2003; 43 Suppl 1():S16-24. PubMed ID: 12887390
[TBL] [Abstract][Full Text] [Related]
15. Engineered botulinum neurotoxins as new therapeutics.
Masuyer G; Chaddock JA; Foster KA; Acharya KR
Annu Rev Pharmacol Toxicol; 2014; 54():27-51. PubMed ID: 24016211
[TBL] [Abstract][Full Text] [Related]
16. Neurotransmitter release from semi-intact synaptosomes.
Tandon A; Tan PK; Bannykh S; Banerjee A; Balch WE
Methods; 1998 Oct; 16(2):198-203. PubMed ID: 9790866
[TBL] [Abstract][Full Text] [Related]
17. Current status and future directions of botulinum neurotoxins for targeting pain processing.
Pellett S; Yaksh TL; Ramachandran R
Toxins (Basel); 2015 Nov; 7(11):4519-63. PubMed ID: 26556371
[TBL] [Abstract][Full Text] [Related]
18. Synaptotagmin-1 docks secretory vesicles to syntaxin-1/SNAP-25 acceptor complexes.
de Wit H; Walter AM; Milosevic I; Gulyás-Kovács A; Riedel D; Sørensen JB; Verhage M
Cell; 2009 Sep; 138(5):935-46. PubMed ID: 19716167
[TBL] [Abstract][Full Text] [Related]
19. Acrosomal exocytosis, a special type of regulated secretion.
Mayorga LS; Tomes CN; Belmonte SA
IUBMB Life; 2007; 59(4-5):286-92. PubMed ID: 17505967
[TBL] [Abstract][Full Text] [Related]
20. Complexins living up to their name--new light on their role in exocytosis.
Stein A; Jahn R
Neuron; 2009 Nov; 64(3):295-7. PubMed ID: 19914176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
